Product Description: Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment[1][2][3].
Applications: Metabolism-sugar/lipid metabolism
Formula: C28H38N2O7S
References: [1]Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114./[2]Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019./[3]Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196.
CAS Number: 1345982-69-5
Molecular Weight: 546.68
Compound Purity: 99.88
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 50 mg/mL (ultrasonic)
Target: Apical Sodium-Dependent Bile Acid Transporter
Deutsch
English
